

The emergence of b-cell maturation antigen (BCMA) tar myeloma

Journal of Oncology Pharmacy Practice

28, 960-968

DOI: [10.1177/10781552211073517](https://doi.org/10.1177/10781552211073517)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophieâ€™s choice for patients with relapsed refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2022, 15, 473-475.	1.0	10
2	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	16
3	Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4	Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 722-726.	0.5	4
5	The Effect of Belantamab Mafodotin on Primary Myelomaâ€™Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5303.	1.8	3